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REVIEW
Abstract: Pediatric obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric
condition associated with broad impairments in functioning. This paper outlines current
etiological theories of OCD, providing a review of neuroanatomical, neurochemical,
neuroimmunological, and cognitive–behavioral explanations. Subsequently, first-line treatment
modalities are discussed (serotonin reuptake inhibitors [SRIs] and cognitive–behavioral therapy
[CBT] with exposure and response prevention [E/RP]) in the context of recent pharmacological,
CBT, and combined trials.
Keywords: OCD, pediatric, etiology, treatment, serotonin reuptake inhibitors, cognitive
behavioral therapy
Pediatric obsessive-compulsive disorder (OCD) is an impairing neurobehavioral
disorder that is generally highly responsive to treatment. OCD is associated with
frontal-subcortical dysfunction, specifically in the cortical-striatal-thalamo-cortical
(CSTC) loops that integrate motoric and cognitive functioning. One of the most
common childhood psychiatric illnesses (Stewart et al 2004), data from recent
epidemiological studies suggest that lifetime prevalence rates of OCD among pediatric
populations range between 1% and 4% (Flament et al 1988; Douglass et al 1995;
Zohar 1999). Recent estimates suggest that 50%–80% of cases have a childhood
onset (Millet et al 2004). Although OCD is less common in younger children, dramatic
increases in prevalence occur during adolescence (Heyman et al 2001), with a bimodal
age of onset distribution, the initial peak incidence occurring prepuberty and the
second in early adulthood (Pauls et al 1995). There is a male predominance (3:2,
male:female ratio; Geller 1998) and earlier age of onset for males (Swedo et al 1989a).
Recent data suggest high rates of comorbid mood, anxiety, attention–disruptive
behavior (eg, attention deficit hyperactivity disorder [ADHD], oppositional defiant
disorder [ODD]), and tic disorders (Geller et al 2003a; POTS 2004).
OCD is characterized by the presence of obsessions (persistent and intrusive
thoughts, ideas, impulses, or images that result in anxiety) and/or compulsions
(repetitive or ritualistic behaviors or mental acts that reduce or prevent anxiety in
response to the obsessive thought) that cause distress, are time-consuming, or interfere
with age-appropriate functioning (APA 2000). Expression of OCD in youth is similar
to that in adulthood, with the exception that children are not required to view their
OCD symptoms as bizarre and unrealistic. Notably, children may not even view
their symptoms as unpleasant (AACAP 1998; Geffken et al 2005). Obsessions and
compulsions are generally linked; compulsions function as behavioral or mental
actions that serve to reduce anxiety elicited by obsessions. Common obsessions and
compulsions in children include worries about harm to self or others, fears of
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contamination, the need for exactness and order, and
religious–moralistic concerns (Swedo et al 1989a). Common
compulsions–rituals include washing–decontamination
rituals (excessive hand washing, showering, or bathing),
confessing, checking–reassurance-seeking, ordering–
arranging, praying, and avoidance.
Etiology
Prior to discussing efficacious treatments, a review of
neuroanatomical (structural and functional), biochemical,
autoimmune–neuroimmunological, and cognitive–
behavioral etiologies of OCD are presented to provide the
correspondence of these mechanisms to the pathophysiology
of OCD and treatment modalities. To date, data suggest that
abnormal brain serotonin metabolism is a key factor in OCD:
serotonin is believed to mediate the expression of OCD
symptoms. Research also suggests that disturbance in the
frontal-limbic (thalamic)-basal ganglia system, areas of the
brain associated with procedural learning and implicit
memory, may relate to OCD symptoms. (The basal ganglia
include the striatum [which includes the caudate nucleus,
putamen, and nucleus accumbens].) It is believed that
overactivity in the orbito-prefrontal cortex may lead to
fastidiousness, excessive concerns, and meticulousness
(Rauch et al 1998). Further, disruption to the head of the
caudate nucleus may impair filtering of information entering
the frontal cortex (Kozak and Foa 1997). Overall, it is
believed that in patients with OCD, there is disruption to
the system that (1) filters information (eg, intrusive thoughts)
from reaching the consciousness and (2) mediates
stereotyped–automated behaviors (Rauch et al 1998). The
following section provides a review in greater detail.
Neuroanatomical
The neurobiology of OCD is associated with abnormalities
in components of the frontal-subcortical circuitry. These
circuits are believed to link the cortex to areas of the brain
involved in the initiation of behavioral responses that are
implemented with minimal conscious attentiveness (Saxena
et al 2001). Moreover, these corticostriatal systems filter
preconscious cognitions and mediate stereotyped behaviors
– dysfunction or overactivity of these systems may explain
intrusive cognitions and ritualized behaviors associated with
OCD (Rauch et al 1998). More specifically, feedback loops
involving orbitofrontal cortex, striatum, thalamus, and the
basal ganglia (ie, the CSTC circuit) may mediate intrusive
thoughts and repetitive behaviors (Saxena et al 1998;
Szeszko et al 2004). Disruption of this feedback system may
lead to symptoms consistent with OCD. Structural imaging
studies lend support for this neurobiological model. For
example, data from volumetric magnetic resonance imaging
(MRI) suggested that patients with OCD had smaller globus
pallidus volumes than normal controls and increased anterior
cingulate gyrus gray matter (Szeszko et al 2004). Rosenberg
and Keshavan (1998) also found increased volume of the
anterior cingulate gyrus among pediatric OCD patients.
Thalamic volumes have been identified to be larger among
pediatric patients with OCD relative to controls (Gilbert et
al 2000). Kim et al (2001) identified increased gray matter
densities in both the cortex and subcortical areas of adult
patients with OCD, especially the left orbitofrontal cortex.
This finding suggesting that this region’s role in inhibitory
motor control may be linked to patients with OCD having
difficulties resisting rituals (Kim et al 2001).
Functional neuroimaging techniques have also been
utilized and have implicated the cortical-striatal pathway
(consisting of the orbitofrontal cortex and the caudate
nucleus) in the pathogenesis of OCD (Rauch and Baxter
1998). Functional MRI (fMRI) has implicated hyperactivity
in the anterior cingulate cortex with symptoms consistent
with OCD (eg, overmonitoring of one’s actions and
behaviors; Ursa et al 2003). Further, Kim et al (2001)
suggested that hyperfunctioning of these circuits may
increase gray matter density observed in volumetric studies.
This is consistent with functional neuroimaging studies
using positron emission
 tomography (PET) (Swedo et al
1989b; McGuire et al 1994; Rauch et al 1994). However,
increased glucose metabolism identified in the globus
pallidus, caudate nucleus, and putamen may be inconsistent
with volumetric studies showing reduced volume of these
structures (Kim et al 2001). Giedd et al (2000) reported
increased volume of the basal ganglia (eg, caudate, putamen,
and globus pallidus). Overall, a recent meta-analysis of
functional neuroimaging identified that differences in the
left orbitogyrus and in the right head of the caudate were
the most consistent markers in distinguishing patients with
OCD from controls (Whiteside et al 2004).
Biochemical
Neurochemical models complement neurobiological
findings from imaging studies implicating serotonin in the
expression of symptoms (Gilbert et al 2000). Although
primary support for neurochemical models of OCD are by
the efficacy of serotonin reuptake inhibitors (SRIs) (see
Flament and Bisserbe 1997; Grados et al 1999; Dougherty
et al 2002), they must be taken in the context ofNeuropsychiatric Disease and Treatment 2006:2(1) 23
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neuroanatomical data (Rauch et al 1998). Specifically,
serotonergic medications modulate serotonin neuro-
transmission within the frontal cortex–thalamocortical
circuits in a way that could explain their therapeutic
effectiveness as antiobsessional (Baxter et al 1996; Rauch
et al 1998). For example, Baxter et al (1992) found (using
PET) decreased thalamic glucose metabolism in adult
patients with OCD after selective serotonin reuptake
inhibitor (SSRI) treatment with fluoxetine. In patients with
pediatric-onset OCD, PET revealed a significant decrease
in orbitofrontal regional cerebral glucose metabolism
following SRI therapy with either clomipramine or
fluoxetine (Swedo et al 1992). The decreased orbitofrontal
glucose metabolism was associated with reductions of OCD
symptoms (Swedo et al 1992). Volumetric MRI studies have
identified decreased thalamic volumes among pediatric
patients with OCD following treatment with paroxetine
(Gilbert et al 2000).
However, Zohar et al (2000) suggested that the
serotonergic hypothesis is not sufficient in explaining the
biochemistry of OCD. Evidence suggests that the
dopaminergic system may also be involved in the
pathophysiology of OCD (Goodman et al 1990). For
example, differences in the dopaminergic system in the
caudate and putamen have been identified in patients with
OCD (Denys et al 2004; van der Wee et al 2004). These
studies suggest the role of the neurotransmitter dopamine
in the pathogenesis of OCD. The glutamatergic system has
also been linked to OCD. Recent research in adolescents
with OCD identified significantly reduced glutamate
concentrations in the anterior cingulate compared with that
in healthy controls (Rosenberg et al 2004).
PANDAS and neuroimmunological–
autoimmune etiologies
Autoimmune factors have also been implicated in the
pathogenesis of pediatric OCD. Swedo et al. (1998) coined
the term Pediatric Autoimmune Neuropsychiatric Disorders
Associated with Streptococcus (PANDAS) – a malfunction
in the immune system associated with the onset and
progression of neuropsychiatric disorders such as OCD and
Tourette’s disorder. Historic and recent literature suggests
that pediatric OCD is more prevalent among patients with
Sydenham’s chorea (SC) that occurs secondary to an
autoimmune reaction to Group A β-hemolytic streptococcus
(GAS). This autoimmune response to GAS cross-reacts with
epitopes (sites on an antigen that interact with specific
antibodies) on the basal ganglia, resulting in motor and
behavioral disturbances (Bronze and Dale 1993). Moreover,
Swedo (1994) reported that a subset of patients with
pediatric OCD presented with several characteristics of SC
but lacked choreiform movements and other central
manifestations of rheumatic fever. Diagnostic criteria for
PANDAS include: (1) the presence of OCD and/or a tic
disorder; (2) prepubertal onset of these symptoms (age 3
years to puberty); (3) episodic–sawtooth course of symptom
severity or abrupt onset; (4) an association with GAS (eg, a
history of rheumatic fever, positive streptococcus throat
culture); and (5) neurological abnormalities such as motoric
hyperactivity or adventitious movements (Swedo et al 1998).
It is believed that the autoimmune response to GAS in
PANDAS results in inflammation of the basal ganglia that
is similar to the mechanism in SC (Leonard and Swedo 2001;
Murphy et al 2004). Studies have found increased
antineuronal antibody binding to basal ganglia tissue in SC
patients that correlate with symptom severity (Husby et al
1976; Kotby et al 1998). Patients with a propensity to
produce high levels of proinflammatory cytokines in
response to GAS may exhibit more severe clinical
manifestations (ie, more intense OCD or tic disorder
symptoms) (Leckman et al 2005). Further, new research
supports antibody-mediated neuronal cell signaling in the
pathogenesis of SC (Kirvan et al 2003). Potential
mechanisms by which autoantibodies cause clinical
manifestations in PANDAS include direct stimulation or
blockade of receptors in the basal ganglia, or immune
complexes promoting inflammation of these brain regions;
studies have found that increased antineuronal antibody
binding to basal ganglia tissue in SC patients correlates well
with symptom severity (Husby et al 1976; Kotby et al 1998).
Overall, the acquired basal ganglia dysfunction following
the GAS autoimmune reaction may result in neuro-
psychiatric and behavioral symptoms consistent with
pediatric OCD including: chorea, tics, obsessions,
compulsions, and hyperactivity (Kurlan and Kaplan 2004).
In addition to PANDAS, there are other noteworthy variants
of pediatric OCD. For example, OCD with a strong family
aggregation of Tourette’s disorder may constitute an
alternative expression of the familial OCD phenotype
(Grados et al 2001). Research suggests putative differences
in pathophysiology between the patients with OCD and
Tourette’s disorder compared with patients with OCD
without Tourette’s (eg, in addition to the serotonergic
neurotransmitter system, dopamine and endogenous opioids
have been implicated in patients with OCD and Tourette’s
disorder (Petter et al 1998). Neuroimaging studies suggestNeuropsychiatric Disease and Treatment 2006:2(1) 24
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the role of the corticostriatal circuits in these patients (Coffey
et al 1998).
Cognitive–behavioral
Behavioral accounts of the etiology of OCD are based on
two stages (Mowrer 1939, 1960): (1) acquisition of fear and
avoidance via classical conditioning, and (2) maintenance
via operant conditioning (Dollard and Miller 1950; Franklin
and Foa 2002). First, a neutral stimulus or event becomes
associated with a feared or unpleasant stimulus. By virtue
of this association, the neutral stimulus becomes conditioned
to elicit distress. This process can include both physical
stimuli (eg, specific locations, contaminated items) and
mental events (eg, dangerous thoughts; Franklin and Foa
2002). Subsequently, behaviors that function to reduce
distress associated with the conditioned stimulus develop.
These behaviors (ie, compulsions or rituals) are operantly
maintained via a negative-reinforcement paradigm, because
they temporarily ameliorate the distress associated with
obsessive thoughts. Over time, these behaviors persist and
become excessive; the reduction in anxiety following a
compulsive behavior precipitates an increase in future
reliance on compulsive behaviors.
Cognitive models are also considered central to the
etiology of OCD (OCCWG 1997; Salkovskis 1999).
Salkovskis (1999) posits that appraisals of intrusive
thoughts, images, and impulses, rather than their
occurrences, characterize OCD. For example, obsessional
patterns develop if intrusive thoughts are interpreted to
indicate responsibility for causing (or failing to prevent)
harm to self or others. In general, obsessions can be
inductively reduced to six intrusive belief patterns
commonly misappraised among patients with OCD: (1)
exaggerated sense of responsibility; (2) overvalued
importance of thoughts; (3) inflated concern about the
importance of controlling one’s thoughts; (4) overestimation
of threat; (5) intolerance of ambiguity–uncertainty; and
(6) perfectionism (OCCWG 1997). Salkovskis (1999)
suggested a circular pattern of intrusive thoughts→
misappraisals→distress-neutralizing behaviors→increased
intrusive thoughts. In other words, patients with OCD
attempt to neutralize intrusive thoughts (eg, a misperceived
threat or responsibility) via motor or cognitive rituals,
avoidance, and reassurance-seeking behavior. This prevents
the disconfirmation of the patient’s fears and facilitates
proliferation of the anxiety – future cognitive intrusions are
more likely followed by continued misappraisal.
Evidence for neurobiological changes following
cognitive–behavioral interventions is inconclusive. For
example, studies have identified metabolic changes in the
thalamus and the caudate nucleus following cognitive–
behavioral therapy (CBT) in adult patients with OCD
(Baxter et al 1992). Contradictory findings were reported
in another study in children with OCD following a 12-week
course of CBT (Benazon et al 2003).
Although further etiological research is essential, overall,
the extant neuroimaging and psychopharmacological studies
combine to provide compelling support for neurobiological
abnormalities in patients with OCD (Flament and Bisserbe
1997). Behavioral and cognitive etiologies are not
inconsistent with these findings: individuals with
neurochemical, neuroimmunological, or neurostructural
abnormalities may be predisposed to behavioral
conditioning. Neuroimaging studies have identified changes
in the cortiostriatial system associated with both symptom
provocation and following effective treatment with both
SRIs and CBT (Rauch and Baxter 1998). Further, the
neuropsychiatric syndrome associated with PANDAS
proposes acquired dysfunction of the basal ganglia – and
integral structure in the CSTC circuit (implicated in
neurostructural and functional assessments). These advances
in neuroimaging, neurochemistry, and neuroimmunology
can elucidate the mechanisms of both OCD symptom
expression and behavioral–pharmacological treatments
(Breiter and Rauch 1996; Grados and Riddle 2001).
Effective interventions
The two empirically supported treatment modalities for
pediatric OCD are: pharmacotherapy with an SSRI or SRI
and CBT with exposure and response prevention (E/RP).
CBT or CBT with concurrent pharmacotherapy using an
SSRI is considered the first-line treatment for pediatric OCD
(AACAP 1998; March et al 2001; Dougherty et al 2002;
POTS 2004).
Pharmacotherapy
The efficacy of pharmacotherapy for OCD in pediatric
populations has been demonstrated in several controlled
trials with SRIs and SSRIs. The most researched SRI in the
treatment of pediatric OCD is the tricyclic antidepressant
(TCA) clomipramine (AACAP 1998; Grados and Riddle
2001). In a double-blind, 8-week, placebo-controlled study
of clomipramine, DeVeaugh-Geiss et al (1992) found that
60% of pediatric patients showed significant improvement.Neuropsychiatric Disease and Treatment 2006:2(1) 25
Pediatric OCD
Patients treated with clomipramine reported a 37% mean
reduction in OCD symptoms compared with 8% for the
placebo group (as assessed using the Children’s Yale-Brown
Obsessive-Compulsive Scale [CYBOCS, Scahill et al
1997]). In another, 10-week controlled trial, Flament et al
(1985) found a significant difference between clomipramine
and placebo, 75% of pediatric patients showing at least
moderate improvement. Other research found that
clomipramine was superior to the noradrenergic reuptake
inhibiting TCA desipramine (Leonard et al 1989). This
crossover trial found that 64% of patients who initially
received clomipramine during their first treatment showed
relapse of OCD symptoms during desipramine treatment
(Leonard et al 1989). Overall, a recent meta-analysis of
pharmacotherapy trials in children identified clomipramine
to be significantly superior over SSRIs in reducing OCD
symptoms (Geller et al 2003b). Nevertheless, the risk profile,
adverse effects, and required EKG and blood-level
monitoring associated with TCAs (eg, antiadrenergic,
anticholinergic, and antihistaminergic adverse effects) are
of concern with clomipramine (AACAP 1998; Geller 1998;
Grados et al 1999).
More recently, a multitude of placebo-controlled trials
has demonstrated the efficacy of SSRIs. In a 20-week,
double-blind, placebo-controlled trial of the SSRI fluoxetine
in children and adolescents with OCD, 44% reductions in
OCD symptoms were reported (Riddle et al 1992). A
13-week controlled trial conducted by Geller et al (2001)
also demonstrated the efficacy of fluoxetine, with 55% of
patients treated with fluoxetine rated as much or very much
improved. Another, 16-week, placebo-controlled trial of
fluoxetine in children reported that 57% of patients
demonstrated significant improved ratings on the CGI
(Liebowitz et al 2002). Several open trials also present
favorable findings for the use of fluoxetine for pediatric
OCD (see Geller 1998 for a review).
Data also support the use of the SSRI sertraline for the
treatment of pediatric OCD. March et al (1998) conducted
a 12-week, multicenter, randomized, placebo-controlled trial
in children and adolescents with OCD. Forty-two percent
of patients receiving sertraline were rated as much or very
much improved. Further, in a 52-week, open-label extension
of the previous study, 71% of children (ages 6–12 years)
and 61% of adolescents (ages 13–18 years) demonstrated
25% decreases on the CYBOCS and were rated as much/
very much improved (Cook et al 2001). More recently,
another multisite, randomized, controlled trial found that
21.4% of pediatric patients entered clinical remission
(defined as CYBOCS ≤ 10) following a 12-week course of
sertraline (POTS 2004).
Finally, controlled trials have found the SSRIs
fluvoxamine and paroxetine to be efficacious and well-
tolerated treatments for children and adolescents with OCD.
Riddle et al (2001) found that 42% of patients responded to
fluvoxamine (based on a 25% reduction on the CYBOCS)
while participating in a 10-week, multicenter, placebo-
controlled trial. A recent 10-week, placebo-controlled trial
of paroxetine for pediatric patients with OCD found that
61% of patients responded to medication (based on a 25%
reduction in the CYBOCS) (Geller et al 2004). In an open-
label trial of paroxetine for pediatric OCD (n = 335), 71%
of patients demonstrated clinical improvement (defined by
a rating of much or very much improved) (Geller et al
2003a). It is noteworthy that the response rate for patients
with a diagnosis of OCD (75%) was significantly greater
than for patients with comorbid psychopathology, eg, ADHD
(56%), tic disorder (53%), and ODD (39%). Overall, patients
with any one comorbid condition had an average response
rate of 68% to paroxetine; patients with any two or three
co-occurring conditions averaged 63% and 59% rates of
response (Geller et al 2003a).
Overall, clinically significant reductions in OCD
symptomology have been documented in children and
adolescents using SSRIs, including fluoxetine, sertraline,
fluvoxamine, and paroxetine, with a relatively minimal side-
effect profile (compared with clomipramine). Based on these
findings, SSRIs are the consensus first-line medication for
pediatric OCD (Grados and Riddle 2001; Liebowitz et al
2002; Geller et al 2003b; POTS 2004). Although there are
no controlled comparisons between these medications in
children, research suggests that the SSRIs are equally
efficacious in children and the specific choice should be
based on the patient’s medical history, concomitant
medications, and the adverse-events profile (Snider and
Swedo 2000; Geller et al 2003b). Poor clinical response to
one SSRI is not necessarily predictive of failure with other
SSRIs, suggesting adequate trials of multiple SSRIs may
be indicated before augmentation (AACAP 1998).
Significant clinical response is unlikely within the first few
weeks of an SSRI – generally, 10–12 weeks at adequate
dosage is necessary to fully evaluate the efficacy of the
medication (AACAP 1998).
In pediatric cases that are unresponsive to CBT and trials
with multiple SSRIs, second-line pharmacological
treatments include augmentation (Dougherty et al 2002).
Grados and Riddle (2001) discuss five augmentationNeuropsychiatric Disease and Treatment 2006:2(1) 26
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approaches for refractory pediatric OCD including:
(1) typical neuroleptics (eg, haloperidol and pimozide);
(2) atypical neuroleptics (eg, olanzapine, risperidone, and
quetiapine); (3) lithium and buspirone; (4) clomipramine;
and (5) benzodiazepines (eg, clonazepam). In the adult OCD
treatment literature, numerous agents have been used in
combination with SRIs for patients whose symptoms have
not been reduced in monotherapy. For example, a limited
number of controlled trials and case series in adults support
the augmentation of SRI pharmacotherapy with either low
doses of the dopamine antagonist haloperidol or the
benzodiazepine clonazepam (for reviews, see Geller 1998;
Dougherty et al 2002). Unlike the adult literature, however,
there is a paucity of empirical data supporting augmentation
strategies for pediatric OCD. Additionally, significant
undesirable side-effects should be considered prior to
prescribing neuroleptics and benzodiazepines in children.
Two pediatric case-series suggest that SSRI augmentation
with clomipramine resulted in marked improvement, but
this combination requires diligent blood, EKG, and side-
effect monitoring (Simeon et al 1990; Figueroa et al 1998).
Lithium carbonate, buspirone, and clonidine have generally
not been efficacious augmentation strategies for treatment-
refractory OCD in adults (see Grados and Riddle 2001 for
a review). There is preliminary support for SSRI
augmentation with atypical antipsychotics for refractory
OCD in adult patients. For example, an 8-week, double-
blind, placebo-controlled trial was performed to determine
the efficacy of risperidone augmentation in adults with
treatment-resistant OCD (Hollander et al 2003). Forty
percent of patients responded to augmentation with
risperidone, although a small sample size limits the
generalization of these findings. Two recent meta-analyses
of off-label use of neuroleptics (haloperidol, risperidone,
olanzapine, and quetiapine; Sareen et al 2004) and atypical
neuroleptics (risperidone, olanzapine, and quetiapine;
Fountoulakis et al 2004) in adults with OCD suggest that
initial findings from open-trials, controlled trials, and case-
series are promising despite a need for substantial further
research. A recent open trial of mirtazapine in adults with
OCD resulted in a 53.3% response rate (Koran et al 2005a).
Preliminary data suggest the potential efficacy of opioids
as alternative therapies for treatment-resistant OCD in adults
using oral morphine (Koran et al 2005b) and tramadol
hydrochloride (Goldsmith et al 1999). Finally, the OCD
subtype etiologically related to Tourette’s disorder (see
above) may require combined therapy of serotonin-reuptake
inhibitors plus neuroleptics or other augmentation strategies
(see Miguel et al 2003 for a review).
Given recent concern regarding the safety of SSRIs in
children, we will outline medications currently approved
by the United States Food and Drug Administration (FDA)
for pediatric use: sertraline (not under age 6 years),
fluoxetine (not under 7), and fluvoxamine–paroxetine (not
under 8). The TCA clomipramine is also FDA approved for
children age 10 and older. On October 15 2005, the FDA
issued a Black Box Warning for antidepressant medications
to alert health care providers to an increased risk of
suicidality (suicidal thinking and behavior) in children and
adolescents being treated with these agents. In light of this
warning, increased attention to symptoms of depression
among pediatric patients being treated with antidepressant
medications appears warranted. This should include formal
assessment of suicidal ideation before and throughout the
course of pharmacological treatment. This Black Box
Warning may suggest a need for expedited research on other
classes of medications (see above; eg, atypical neuroleptic).
An additional implication of this warning may be to attempt
an adequate trial of the cognitive-behavioral therapy (the
other first-line treatment for pediatric OCD; see below) prior
to pharmacological intervention.
Cognitive–behavioral therapy
The efficacy of CBT in children has been demonstrated in
numerous open trials (March et al 1994; Franklin et al 1998;
Thienemann et al 2001; Benazon et al 2002; Piacentini et al
2002) and three controlled trials (de Hann et al 1998; Barrett
et al 2004; POTS 2004). Indeed, treatment response rates
in the extant CBT trials was quite high, ranging from 57%
to 88% (Bolton et al 1995; Franklin et al 1998; Benazon et
al 2002; Piacentini et al 2002; Barrett et al 2004).
Preliminary data also support the use of CBT for PANDAS
(Storch et al 2004). Further, unlike pharmacotherapies (for
which relapse is not uncommon when medication is
discontinued) treatment gains from CBT commonly endure
after therapy is completed (AACAP 1998). In contrast, CBT
with E/RP for OCD is distinguished from other “talk-
therapies” with no supported efficacy in the extant literature.
Generally, no demonstrated effects for play-based,
supportive, insight-oriented, relaxation, psychoanalytic, and
psychodynamic therapies have been identified for the
treatment of pediatric OCD (AACAP 1998; March and
Mulle 1998; March et al 2001; Franklin and Foa 2002;
Piacentini and Langley 2004). Aspects of CBT for OCDNeuropsychiatric Disease and Treatment 2006:2(1) 27
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are discussed below; treatment manuals are available for
further detail, eg Lewin et al (2005); March and Mulle
(1998).
Efficacious CBT protocols consist of exposure (placing
the patient in situations that elicit anxiety related to their
obsessions), response prevention (deterring the compulsive
or ritualistic behaviors, which may serve to reduce or avoid
anxiety, from occurring), and cognitive therapy (training
the patient to identify and reframe anxiety-provoking
cognitions) (Lewin et al 2005). Prior to beginning E/RP,
education about OCD is provided to both the patient and
family (often in context of a story for young children). It is
explained to the patient and his/her family that compulsions–
rituals–avoidance are (1) ineffective at reducing anxiety in
the long term; (2) interfere with normal functioning; and
(3) prevent the child from developing more effective
strategies for coping with anxiety. Specifically, because
compulsive behaviors–rituals actually function to reduce
anxiety in the short term (and make the child feel better,
albeit temporarily), these behaviors are more likely to be
used the next time an obsessive thought occurs (Franklin
and Foa 2002).
Also at this phase of treatment, a “fear-hierarchy” is
developed. The hierarchy consists of situations the patient
avoids or for which the patient would find it difficult to
inhibit compensatory overt or mental rituals. The therapist
assists the family and patient to develop a list of stimuli–
situations that would elicit a range of symptoms from mild
discomfort to incapacitating anxiety in the child (if
compensatory compulsions–rituals are prevented). The child
is then instructed to rate how anxiety provoking each
situation would be, on a scale of 0 (no anxiety) to 100
(extreme anxiety). The hierarchy consists of situations the
patient avoids or for which the patient finds it difficult to
inhibit rituals. Subjective units of disturbance scales (SUDS)
with a narrower range (eg, 0–10) may be more appropriate
for younger children with OCD who might have difficulty
selecting from a wide range. March and Mulle’s (1998) fear
thermometer can be helpful in establishing SUDS ratings
with younger children.
Next, the therapist and child begin hierarchy-based
E/RP according to stimuli identified on the patient’s fear-
hierarchy (typically starting at the least-distressing situation
and progressing up the hierarchy during subsequent
sessions). E/RP involves gradual exposure to anxiety-
provoking stimuli while refraining from rituals (Meyer
1966); the procedure is based on the assumption that
compulsions are performed to reduce and/or avoid anxiety
associated with obsessions (ie, obsessions and compulsions
are functionally related; Franklin and Foa 2002). The E/RP
exercise provides the patient with objective experiences to
contradict the inaccurate expectations that motivate rituals
(Foa and Kozak 1996). During E/RP exercises, the exposure
component relies on the gradual attenuation of anxiety after
sufficient duration or contact with a feared stimulus (March
et al 2001). Successive exposures with the feared stimulus
result in both decreased elevations in anxiety and more rapid
attenuation of distress. The response-prevention component
is based on the assumption that rituals–compulsions function
to reduce anxiety in the short term. However, the short-term
escape–avoidance of anxiety actually maintains–increases
the likelihood of compulsive behavior as well as continued
distress via negative reinforcement. Therefore, individuals
with OCD rely on rituals–avoidance to mitigate distress and
never habituate to anxiety. Therefore, the function of E/RP
is for the individual to terminate the negative reinforcement
paradigm (ie, ending the compulsive behavior–avoidance)
so that anxiety can be reduced via habituation instead of by
rituals. In sum, treatment should include concurrent E/RP.
Taken together, these treatment components teach youth with
OCD that (1) the anxiety they experience in response to
OCD-triggers will come down on its own without having to
resort to rituals and (2) that even without rituals, the
occurrence of the dreaded outcome is highly unlikely.
In addition to E/RP, adjunctive cognitive strategies are
utilized with pediatric patients. Salkovskis (1999) outlined
an OCD-specific form of cognitive therapy with adults,
which may be applied to children. However, younger
children, and those with impaired cognitive functioning,
receive fewer and less sophisticated cognitive components
to treatment due to developmental and cognitive limitations.
A child’s age, cognitive functioning, and insight into the
nature of his/her OCD is paramount in determining the
direction of treatment, as introduction of cognitive
components of therapy depends on the child’s developmental
level and insight. Cognitive techniques include cognitive
restructuring (eg, teaching the patient to challenge anxiety-
provoking thoughts and/or the necessity of performing
compulsive behaviors). In other words, the patient should
construct and validate alternative, less threatening
explanations for intrusive thoughts–images–doubts rather
than focusing on disconfirming negative beliefs (Salkovskis
1999). If intrusive thoughts are not negatively interpreted,
they are less likely to be viewed as significant. Despite theNeuropsychiatric Disease and Treatment 2006:2(1) 28
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utility of cognitive restructuring for children with OCD
along with E/RP, clinicians must be ever-alert to the
possibility that a “re-framed” thought can become a ritual
for a child with OCD. For example, during therapy a child
is taught to restructure fears about using a public toilet, such
as, “It’s okay to sit on the toilet – I won’t get sick.” However,
it is not uncommon for children to replace a ritual with a
mental ritual (eg, needing to repeat the aforementioned
statement) in order to reduce anxiety, thus maintaining OCD.
Teaching children coping phrases and self-talk (eg, “I can
beat my OCD!” or “It may be hard, but I can do it”) can
assist children to mange obsessions but may be less likely
to become replacement rituals. March and Mulle (1998)
outline examples of self-talk strategies.
Although CBT for OCD is typically conducted via
weekly 1-hour sessions (eg, March et al 1994; Benazon et
al 2002; Barrett et al 2004; POTS 2004), an alternative CBT
format has been utilized for the treatment of refractory
pediatric OCD. Intensive cognitive behavioral therapy
(I-CBT) for OCD involves techniques similar to traditional
CBT with E/RP (Lewin et al 2005). However, the frequency
and duration of the sessions are increased from weekly
50-minute sessions to daily 90-minute sessions. Research
suggests that prolonged, continuous exposures are superior
to shorter, intermittent exposures (Rabavilas et al 1976).
Preliminary research supports the use of I-CBT in cases of
difficult-to-treat pediatric OCD. In one open trial of I-CBT
for refractory pediatric OCD, all five children who
participated were treatment responders and showed
significant decreases in OCD symptomatology (Storch and
Geffken 2004). A noncontrolled trial by Franklin et al (1998)
and several case reports (Franklin et al 2001; Storch et al
2004; Storch et al 2005; Fernandez et al in press) also found
support for I-CBT. Although a randomized controlled study
of I-CBT in adults produced promising results (Abramowitz
et al 2003), there has yet to be a controlled trial of I-CBT
versus weekly CBT for OCD in children and adolescents.
There are several prognostic indicators of a positive
response to CBT for pediatric OCD. First, family
involvement is central to the success of CBT for pediatric
OCD (Knox et al 1996; Barrett et al 2004). In addition to
extinction and differential reinforcement procedures (see
Francis 1988; Fernandez et al in press), parents and families
can provide substantial emotional and instrumental support
with treatment. Other positive indicators include the child’s
willingness to cooperate with treatment, the presence of
overt rituals, motivation to eliminate rituals–symptoms,
developmental level, and the ability to monitor and report
symptoms (March et al 2001). Conversely, several putative
factors are associated with a poor response to CBT. These
include extensive co-occurring psychiatric conditions (see
Geller et al 2003a), impaired cognitive development (eg,
developmental delay, mental retardation, and very young
children; AACAP 1998); and individuals with poor insight
into the senselessness of their obsessions and compulsions
(Franklin and Foa 2002). Certain family factors may
negatively influence CBT for OCD. For example, parents
pushing their children too hard during E/RP (eg, moving
up the hierarchy too quickly prior to assignment by the
therapist), parents sabotaging exposures and/or being overly
punitive (eg, throwing an item the child believes to be
contaminated at the child without warning), or parents with
OCD or other anxiety disorders themselves. Further research
in the area of family factors and treatment outcomes appears
warranted. Although children with OCD and Tourette’s
disorder are considered to be less responsive to treatment,
CBT is considered the first-line treatment for these patients
(Miguel et al 2003).
Conclusions
CBT alone or CBT with concurrent SSRI therapy are
considered the first-line treatments (POTS 2004). Although
there are few controlled comparisons between CBT,
medication, and concomitant CBT and SRI in pediatric
samples with OCD, CBT was found to be superior to
medication alone (clomipramine, de Hann et al 1998;
sertraline, POTS 2004). In addition, supplemental CBT has
been demonstrated to be effective following unsuccessful
fluoxetine treatment for adults with OCD (Kampman et al
2002).
Despite the efficacy of CBT with E/RP, the lack of
professionals trained in CBT for OCD is among the greatest
barriers to successful treatment (AACAP 1998). This limited
access to specialists familiar with empirically supported
treatments (eg, CBT with E/RP) may result in the
prescription of pharmacotherapy alone and/or other
psychotherapies that have not been demonstrated as
efficacious (eg, play therapy, psychoanalytical therapy,
insight-oriented therapy). For example, in a national survey
of 79 clinicians treating pediatric OCD, less than 33%
reported using exposure–response prevention (or similar
techniques), despite rating CBT as a favorable approach to
treatment (Valderhaug et al 2004). Additionally, Heyman et
al (2001) found that only 36% of the families of children
with OCD had consulted a healthcare practitioner; only 12%
of those children were referred for specialized mental healthNeuropsychiatric Disease and Treatment 2006:2(1) 29
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services. Similarly, Flament et al (1988) found that only
20% of children with OCD were receiving mental health
services.
Overall, despite recent advances, considerable further
research is needed to bolster etiological and interventional
understanding of pediatric OCD. As evidenced by the studies
presented in this review, clinical research trials and
neurobiological investigations are convergent, not parallel,
courses of research. That is, advances in neurochemistry
guide pharmacotherapy while the efficacy of CBT might
suggest brain structures for more detailed neuroimaging
studies.
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